UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025397
Receipt number R000029236
Scientific Title Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial
Date of disclosure of the study information 2016/12/27
Last modified on 2017/08/09 14:47:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial

Acronym

Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial

Scientific Title

Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial

Scientific Title:Acronym

Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial

Region

Japan


Condition

Condition

Healthy volunteers
Hypertension

Classification by specialty

Cardiology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate blood pressure-lowering effect of Salacia oblonga extract comparing two doses in high-normal blood pressure or grade I hypertension subjects.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

3-week change in home blood pressure

Key secondary outcomes

3-week change in ankle-brachial index (ABI) and office blood pressure


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Dose comparison

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Subjects receive 6 tablets/day (2 tablets/time) containing a total of 180 mg of Salacia oblonga extract for 3 weeks.

Interventions/Control_2

Subjects receive 6 tablets/day (2 tablets/time) containing a total of 540 mg of Salacia oblonga extract for 3 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Diagnosed as high-normal blood pressure or grade I hypertension through health checks twice or more in three years
2) With habit of eating 3 meals a day

Key exclusion criteria

1) Taking antihypertensive
2) Taking medicines for chronic disease other than antihypertensive
3) Taking functional food that may affect the trial
4) Participation in any clinical trial within 90 days of the commencement of the trial
5) In pregnancy or nursing a child
6) Judged as ineligible by clinical investigators

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Fumiko Higashikawa

Organization

Hiroshima University, Institute of Biomedical & Health Sciences

Division name

Project Research Center for Clinical Trial and Preventive Medicine

Zip code


Address

Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN

TEL

082-257-1533

Email

fumiko@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Fumiko Higashikawa

Organization

Hiroshima University, Institute of Biomedical & Health Sciences

Division name

Project Research Center for Clinical Trial and Preventive Medicine

Zip code


Address

Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN

TEL

082-257-1533

Homepage URL


Email

fumiko@hiroshima-u.ac.jp


Sponsor or person

Institute

Hiroshima University

Institute

Department

Personal name



Funding Source

Organization

TAKAMA Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

広島大学病院(広島県)


Other administrative information

Date of disclosure of the study information

2016 Year 12 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 12 Month 22 Day

Date of IRB


Anticipated trial start date

2017 Year 02 Month 10 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 12 Month 26 Day

Last modified on

2017 Year 08 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029236


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name